Cassiopea

IFBC was mandated by the board of directors of Cassiopea to prepare a Fairness Opinion assessing the public exchange offer made by Cosmo Pharmaceuticals NV from a financial point of view. As a qualified evaluator pursuant to Article 30(6) Takeover Ordinance, IFBC is suitably qualified to prepare Fairness Opinions. Cassiopea S.p.A. is an Italian specialty pharmaceutical company listed on the SIX Swiss Exchange focusing on the development and commercialization of innovative prescription drugs for the treatment of highly prevalent skin diseases.